Copyright Reports & Markets. All rights reserved.

Global Neurodegenerative Diseases Drug Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Immunomodulator
    • 1.4.3 Interferons
    • 1.4.4 Decarboxylase Inhibitors
    • 1.4.5 Dopamine Agonists
    • 1.4.6 Others
  • 1.5 Market by Application
    • 1.5.1 Global Neurodegenerative Diseases Drug Market Share by Application: 2020 VS 2026
    • 1.5.2 Multiple Sclerosis
    • 1.5.3 Parkinson’s Disease
    • 1.5.4 Alzheimer’s Disease
    • 1.5.5 Spinal Muscular Atrophy (SMA)
    • 1.5.6 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Neurodegenerative Diseases Drug Market Perspective (2015-2026)
  • 2.2 Neurodegenerative Diseases Drug Growth Trends by Regions
    • 2.2.1 Neurodegenerative Diseases Drug Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Neurodegenerative Diseases Drug Historic Market Share by Regions (2015-2020)
    • 2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Neurodegenerative Diseases Drug Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Neurodegenerative Diseases Drug Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Neurodegenerative Diseases Drug Players by Market Size
    • 3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2015-2020)
    • 3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Neurodegenerative Diseases Drug Market Concentration Ratio
    • 3.2.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2019
  • 3.3 Neurodegenerative Diseases Drug Key Players Head office and Area Served
  • 3.4 Key Players Neurodegenerative Diseases Drug Product Solution and Service
  • 3.5 Date of Enter into Neurodegenerative Diseases Drug Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2015-2020)
  • 4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2021-2026)

5 Neurodegenerative Diseases Drug Breakdown Data by Application (2015-2026)

  • 5.1 Global Neurodegenerative Diseases Drug Market Size by Application (2015-2020)
  • 5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Neurodegenerative Diseases Drug Market Size (2015-2020)
  • 6.2 Neurodegenerative Diseases Drug Key Players in North America (2019-2020)
  • 6.3 North America Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
  • 6.4 North America Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Neurodegenerative Diseases Drug Market Size (2015-2020)
  • 7.2 Neurodegenerative Diseases Drug Key Players in Europe (2019-2020)
  • 7.3 Europe Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
  • 7.4 Europe Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

8 China

  • 8.1 China Neurodegenerative Diseases Drug Market Size (2015-2020)
  • 8.2 Neurodegenerative Diseases Drug Key Players in China (2019-2020)
  • 8.3 China Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
  • 8.4 China Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Neurodegenerative Diseases Drug Market Size (2015-2020)
  • 9.2 Neurodegenerative Diseases Drug Key Players in Japan (2019-2020)
  • 9.3 Japan Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
  • 9.4 Japan Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Neurodegenerative Diseases Drug Market Size (2015-2020)
  • 10.2 Neurodegenerative Diseases Drug Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

11 India

  • 11.1 India Neurodegenerative Diseases Drug Market Size (2015-2020)
  • 11.2 Neurodegenerative Diseases Drug Key Players in India (2019-2020)
  • 11.3 India Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
  • 11.4 India Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Neurodegenerative Diseases Drug Market Size (2015-2020)
  • 12.2 Neurodegenerative Diseases Drug Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Neurodegenerative Diseases Drug Market Size by Type (2015-2020)
  • 12.4 Central & South America Neurodegenerative Diseases Drug Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Biogen
    • 13.1.1 Biogen Company Details
    • 13.1.2 Biogen Business Overview and Its Total Revenue
    • 13.1.3 Biogen Neurodegenerative Diseases Drug Introduction
    • 13.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2015-2020))
    • 13.1.5 Biogen Recent Development
  • 13.2 Pfizer
    • 13.2.1 Pfizer Company Details
    • 13.2.2 Pfizer Business Overview and Its Total Revenue
    • 13.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
    • 13.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.2.5 Pfizer Recent Development
  • 13.3 Roche
    • 13.3.1 Roche Company Details
    • 13.3.2 Roche Business Overview and Its Total Revenue
    • 13.3.3 Roche Neurodegenerative Diseases Drug Introduction
    • 13.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.3.5 Roche Recent Development
  • 13.4 Novartis
    • 13.4.1 Novartis Company Details
    • 13.4.2 Novartis Business Overview and Its Total Revenue
    • 13.4.3 Novartis Neurodegenerative Diseases Drug Introduction
    • 13.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.4.5 Novartis Recent Development
  • 13.5 Sanofi
    • 13.5.1 Sanofi Company Details
    • 13.5.2 Sanofi Business Overview and Its Total Revenue
    • 13.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
    • 13.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.5.5 Sanofi Recent Development
  • 13.6 Teva Pharmaceuticals
    • 13.6.1 Teva Pharmaceuticals Company Details
    • 13.6.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
    • 13.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
    • 13.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.6.5 Teva Pharmaceuticals Recent Development
  • 13.7 Orion Pharma Ltd
    • 13.7.1 Orion Pharma Ltd Company Details
    • 13.7.2 Orion Pharma Ltd Business Overview and Its Total Revenue
    • 13.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
    • 13.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.7.5 Orion Pharma Ltd Recent Development
  • 13.8 UCB S.A
    • 13.8.1 UCB S.A Company Details
    • 13.8.2 UCB S.A Business Overview and Its Total Revenue
    • 13.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
    • 13.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.8.5 UCB S.A Recent Development
  • 13.9 ACADIA Pharmaceuticals Inc.
    • 13.9.1 ACADIA Pharmaceuticals Inc. Company Details
    • 13.9.2 ACADIA Pharmaceuticals Inc. Business Overview and Its Total Revenue
    • 13.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
    • 13.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.9.5 ACADIA Pharmaceuticals Inc. Recent Development
  • 13.10 Lundbeck Pharmaceuticals Italy S.p.A.
    • 13.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Details
    • 13.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview and Its Total Revenue
    • 13.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
    • 13.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 13.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
  • 13.11 Mitsubishi Tanabe Pharma America
    • 10.11.1 Mitsubishi Tanabe Pharma America Company Details
    • 10.11.2 Mitsubishi Tanabe Pharma America Business Overview and Its Total Revenue
    • 10.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
    • 10.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2015-2020)
    • 10.11.5 Mitsubishi Tanabe Pharma America Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Neurodegenerative Diseases Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neurodegenerative Diseases Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Biogen
    Pfizer
    Roche
    Novartis
    Sanofi
    Teva Pharmaceuticals
    Orion Pharma Ltd
    UCB S.A
    ACADIA Pharmaceuticals Inc.
    Lundbeck Pharmaceuticals Italy S.p.A.
    Mitsubishi Tanabe Pharma America

    Market segment by Type, the product can be split into
    By Drug Class
    Immunomodulator
    Interferons
    Decarboxylase Inhibitors
    Dopamine Agonists
    Others
    By Route of Administration
    Oral
    Injection
    Transdermal
    Market segment by Application, split into
    Multiple Sclerosis
    Parkinson’s Disease
    Alzheimer’s Disease
    Spinal Muscular Atrophy (SMA)
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Neurodegenerative Diseases Drug status, future forecast, growth opportunity, key market and key players.
    To present the Neurodegenerative Diseases Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Neurodegenerative Diseases Drug are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now